A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group Study
- 1 December 1990
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 39 (3) , 239-243
- https://doi.org/10.1016/0090-8258(90)90244-f
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Cancer statistics, 1990CA: A Cancer Journal for Clinicians, 1990
- Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: A Southwest Oncology Group studyGynecologic Oncology, 1989
- Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: A Southwest Oncology Group studyGynecologic Oncology, 1989
- Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus corynebacterium parvum (a gynecologic oncology group study)Gynecologic Oncology, 1986
- Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer modelAmerican Journal of Obstetrics and Gynecology, 1977
- CELL-MEDIATED-IMMUNITY AND BLOCKING FACTOR IN OVARIAN CARCINOMA1976
- Inhibitory effect of prolongedcorynebacterium parvum and cyclophosphamide administration on the growth of established tumorsCancer, 1975
- Demonstration of tumor-associated antigens in human gynecologic malignanciesAmerican Journal of Obstetrics and Gynecology, 1973
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958